Pregnancy Loss
Conditions
Brief summary
Using low-molecular-weight heparin (LMWH), outcomes such as live birth rate and the occurrence of pregnancy complications are some of the variables reported in some studies, with varying degrees of success. The present study aimed to compare the role of LMWH in unexplained recurrent pregnancy loss.
Interventions
DRUGLow molecular weight heparin
A daily dose of 40 mg of low-molecular-weight heparin (LMWH) subcutaneously was given to the patients.
Sponsors
RESnTEC, Institute of Research
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to 44 Years
Healthy volunteers
No
Inclusion criteria
* Pregnant females between 18 and 44 years of age * Gestational age above 8 weeks * A history of ≥3 consecutive first trimester pregnancy losses
Exclusion criteria
* Patients with systemic lupus erythematosus * Positive IgG and IgM anticardiolipin antibodies * Positive for thrombophilia screening * Any platelet function abnormality or a previous thromboembolic event requiring anticoagulant therapy (including heparin, aspirin or warfarin) * Sensitive to acetylsalicylic acid, heparin, or warfarin * Patients with any genetic, anatomical, or hormonal cause of recurrent pregnancy loss
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Efficacy of Low-Molecular-Weight Heparin | 32 weeks | Efficacy was labeled as yes in terms of live births after the age of viability, i.e., 24 weeks of gestation. |
Countries
Pakistan
Outcome results
None listed